GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $8.18.

A number of research analysts recently commented on the stock. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. Morgan Stanley reduced their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Barclays lowered their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Citigroup reduced their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. National Bank of Canada FI raised its position in shares of GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock valued at $39,000 after buying an additional 2,151 shares in the last quarter. RPO LLC acquired a new position in GoodRx during the fourth quarter valued at approximately $52,000. Versor Investments LP bought a new stake in GoodRx during the fourth quarter worth $54,000. Verus Capital Partners LLC bought a new stake in GoodRx during the fourth quarter worth $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of GoodRx in the 4th quarter valued at $56,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Down 6.1 %

GoodRx stock opened at $4.64 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company’s 50-day moving average is $4.73 and its 200-day moving average is $5.68. The firm has a market capitalization of $1.77 billion, a PE ratio of -154.67, a P/E/G ratio of 2.46 and a beta of 1.25. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.